Toll Free: 1-888-928-9744

Tardive Dyskinesia Global Clinical Trials Review, H1, 2016

Published: Mar 16, 2016 | Pages: 60 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tardive Dyskinesia Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Tardive Dyskinesia Global Clinical Trials Review, H1, 2016" provides an overview of Tardive Dyskinesia clinical trials scenario. This report provides top line data relating to the clinical trials on Tardive Dyskinesia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Countries Contributing to Clinical Trials in Middle East and Africa 13 Clinical Trials by G7 Countries: Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials 14 Clinical Trials by Phase in G7 Countries 15 Clinical Trials in G7 Countries by Trial Status 16 Clinical Trials by E7 Countries: Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials 17 Clinical Trials by Phase in E7 Countries 18 Clinical Trials in E7 Countries by Trial Status 19 Clinical Trials by Phase 20 In Progress Trials by Phase 21 Clinical Trials by Trial Status 22 Clinical Trials by End Point Status 23 Subjects Recruited Over a Period of Time 24 Clinical Trials by Sponsor Type 25 Prominent Sponsors 26 Top Companies Participating in Tardive Dyskinesia Therapeutics Clinical Trials 27 Prominent Drugs 28 Latest Clinical Trials News on Tardive Dyskinesia 29 Mar 02, 2016: Neurocrine Biosciences Announces the Acceptance of Three Scientific Abstracts for Valbenazine (NBI-98854) at the 68th Annual Meeting of the American Academy of Neurology in Vancouver April 2016 29 Clinical Trial Profile Snapshots 30 Appendix 57 Abbreviations 57 Definitions 57 Research Methodology 58 Secondary Research 58 About GlobalData 59 Contact Us 59 Disclaimer 59 Source 60
List of Tables
Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Region, 2016* 6 Tardive Dyskinesia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8 Tardive Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Tardive Dyskinesia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 10 Tardive Dyskinesia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11 Tardive Dyskinesia Therapeutics Clinical Trials, North America, Top Countries, 2016* 12 Tardive Dyskinesia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13 Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14 Tardive Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Tardive Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17 Tardive Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Tardive Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Phase, 2016* 20 Tardive Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21 Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Tardive Dyskinesia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Tardive Dyskinesia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Tardive Dyskinesia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25 Tardive Dyskinesia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Tardive Dyskinesia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Tardive Dyskinesia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28


List of Figures
Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Tardive Dyskinesia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Tardive Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Tardive Dyskinesia Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 10 Tardive Dyskinesia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11 Tardive Dyskinesia Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12 Tardive Dyskinesia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13 Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14 Tardive Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Tardive Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Tardive Dyskinesia to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17 Tardive Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Tardive Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20 Tardive Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21 Tardive Dyskinesia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Tardive Dyskinesia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Tardive Dyskinesia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Tardive Dyskinesia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25 Tardive Dyskinesia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Tardive Dyskinesia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Tardive Dyskinesia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28 GlobalData Methodology 58

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...

Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3D

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify